Published in J Bone Miner Res on January 18, 2005
New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol (2011) 3.97
Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res (2013) 1.73
Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res (2009) 1.21
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest (2014) 1.13
Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone (2014) 0.94
The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res (2008) 0.93
Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. Bone (2013) 0.88
Bone: Use of bisphosphonates in children-proceed with caution. Nat Rev Endocrinol (2009) 0.86
Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates. J Child Orthop (2012) 0.85
Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report. Acta Orthop (2012) 0.84
Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. Eur J Pediatr (2007) 0.84
Hypermobility syndrome increases the risk for low bone mass. Clin Rheumatol (2005) 0.84
Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporos Int (2011) 0.83
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int (2011) 0.83
RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res (2010) 0.83
Recognizing and treating secondary osteoporosis. Nat Rev Rheumatol (2012) 0.82
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. J Bone Miner Res (2016) 0.82
Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: implications for clinical care. Pediatr Res (2015) 0.82
Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord (2014) 0.81
Effect of bisphosphonates on the rapidly growing male murine skeleton. Endocrinology (2014) 0.81
Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study. Health Qual Life Outcomes (2014) 0.81
Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial. J Musculoskelet Neuronal Interact (2016) 0.81
Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta. Stem Cells Dev (2013) 0.79
Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol (2006) 0.78
RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. Eur J Histochem (2015) 0.77
Pediatric DXA: clinical applications. Pediatr Radiol (2007) 0.77
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. J Osteoporos (2016) 0.76
Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta. Int J Med Sci (2013) 0.76
An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. Osteoporos Int (2013) 0.76
Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta. Skeletal Radiol (2012) 0.76
The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep (2016) 0.75
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Association between joint hypermobility, scoliosis, and cranial base anomalies in paediatric Osteogenesis imperfecta patients: a retrospective cross-sectional study. BMC Musculoskelet Disord (2014) 0.75
Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up. Acta Orthop (2013) 0.75
A better index of body adiposity. Obesity (Silver Spring) (2011) 7.53
Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med (2008) 5.34
Natural history of alkaptonuria. N Engl J Med (2002) 5.32
New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol (2011) 3.97
Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet (2007) 3.84
Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer (2008) 3.49
Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med (2006) 2.97
Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. Arch Phys Med Rehabil (2008) 2.90
Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab (2003) 2.53
Labor progression and risk of cesarean delivery in electively induced nulliparas. Obstet Gynecol (2005) 2.44
Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med (2010) 2.44
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol (1985) (2005) 2.37
A prospective study of psychological predictors of body fat gain among children at high risk for adult obesity. Pediatrics (2006) 2.28
Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone (2003) 2.27
Orthopedic complications of overweight in children and adolescents. Pediatrics (2006) 2.25
Hypo-functional SLC26A4 variants associated with nonsyndromic hearing loss and enlargement of the vestibular aqueduct: genotype-phenotype correlation or coincidental polymorphisms? Hum Mutat (2009) 2.25
Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med (2003) 2.18
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab (2011) 1.98
Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab (2004) 1.92
Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. J Biol Chem (2008) 1.92
Novel applications of ultrasound technology to visualize and characterize myofascial trigger points and surrounding soft tissue. Arch Phys Med Rehabil (2009) 1.90
Multiple testing with minimal assumptions. Biom J (2008) 1.87
Constraint-induced therapy in stroke: magnetic-stimulation motor maps and cerebral activation. Neurorehabil Neural Repair (2003) 1.83
Reassessing the labor curve in nulliparous women. Am J Obstet Gynecol (2002) 1.81
COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum Mutat (2011) 1.77
Maternal prepregnancy overweight and obesity and the pattern of labor progression in term nulliparous women. Obstet Gynecol (2004) 1.76
High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med (2002) 1.74
Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res (2013) 1.73
Use of nitisinone in patients with alkaptonuria. Metabolism (2005) 1.70
Impact of computer-aided detection in a regional screening mammography program. AJR Am J Roentgenol (2005) 1.67
How gender impacts career development and leadership in rehabilitation medicine: a report from the AAPM&R research committee. Arch Phys Med Rehabil (2007) 1.66
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics (2006) 1.63
Structural heterogeneity of type I collagen triple helix and its role in osteogenesis imperfecta. J Biol Chem (2007) 1.60
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant (2011) 1.54
Cancer-related fatigue: implications for breast cancer survivors. Cancer (2012) 1.53
Hypothesis: Neonatal respiratory distress may be related to asymptomatic colonization with group B streptococci. Pediatr Infect Dis J (2006) 1.52
Bone mineral density and fractures in Turner syndrome. Am J Med (2003) 1.51
Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res (2004) 1.47
Maternal vitamin B12 status and risk of neural tube defects in a population with high neural tube defect prevalence and no folic Acid fortification. Pediatrics (2009) 1.44
Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in african americans. Obes Res (2004) 1.43
Disordered-eating attitudes in relation to bone mineral density and markers of bone turnover in overweight adolescents. J Adolesc Health (2009) 1.42
Low bone mass in premenopausal women with depression. Arch Intern Med (2007) 1.38
Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing. J Biol Chem (2005) 1.37
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab (2012) 1.36
Birthweight and gestational age effects on motor and social development. Paediatr Perinat Epidemiol (2002) 1.36
Sex differences in visceral adipose tissue volume among African Americans. Am J Clin Nutr (2002) 1.35
Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab (2009) 1.33
Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes (2011) 1.32
Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (2003) 1.28
Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix. Hum Mutat (2012) 1.25
Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix. J Biol Chem (2006) 1.24
Methodological challenges in studying labour progression in contemporary practice. Paediatr Perinat Epidemiol (2006) 1.24
Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res (2009) 1.21
Mapping of SPARC/BM-40/osteonectin-binding sites on fibrillar collagens. J Biol Chem (2008) 1.21
A prospective surveillance model for rehabilitation for women with breast cancer. Cancer (2012) 1.21
Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab (2011) 1.19
Folate-related gene polymorphisms as risk factors for cleft lip and cleft palate. Birth Defects Res A Clin Mol Teratol (2008) 1.18
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr (2008) 1.17
Objective sonographic measures for characterizing myofascial trigger points associated with cervical pain. J Ultrasound Med (2011) 1.17
Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo. J Bone Miner Res (2010) 1.14
Adiposity and human regional body temperature. Am J Clin Nutr (2009) 1.12
Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res (2008) 1.12
Comparison of methods to assess change in children's body composition. Am J Clin Nutr (2004) 1.11
An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res (2004) 1.11
Comparison of labor progression between induced and noninduced multiparous women. Obstet Gynecol (2006) 1.10
Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI. Matrix Biol (2007) 1.09
Testing reported associations of genetic risk factors for oral clefts in a large Irish study population. Birth Defects Res A Clin Mol Teratol (2010) 1.08
Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol (2004) 1.08
Nanoscale morphology of Type I collagen is altered in the Brtl mouse model of Osteogenesis Imperfecta. J Struct Biol (2010) 1.08
Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther (2011) 1.08
Evaluation of common genetic variants in 82 candidate genes as risk factors for neural tube defects. BMC Med Genet (2012) 1.08
A founder mutation in LEPRE1 carried by 1.5% of West Africans and 0.4% of African Americans causes lethal recessive osteogenesis imperfecta. Genet Med (2012) 1.08
Musculoskeletal findings and disability in alkaptonuria. J Rheumatol (2006) 1.07
Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing in the endoplasmic reticulum collagen prolyl 3-hydroxylation complex. Hum Mol Genet (2009) 1.07
Assessment of myofascial trigger points (MTrPs): a new application of ultrasound imaging and vibration sonoelastography. Conf Proc IEEE Eng Med Biol Soc (2008) 1.07
Multisegment foot motion during gait: proof of concept in rheumatoid arthritis. J Rheumatol (2004) 1.06
Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. Metabolism (2005) 1.06
Popcorn calcification in osteogenesis imperfecta: incidence, progression, and molecular correlation. Am J Med Genet A (2008) 1.05
Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res (2012) 1.04
Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest (2009) 1.04
Ultrasound imaging distinguishes between normal and weak muscle. Arch Phys Med Rehabil (2004) 1.04
Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res (2003) 1.02
Neurotrophin-3 improves functional constipation. Am J Gastroenterol (2003) 1.02
Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol (2003) 1.01
Estimates of body fat in children by Hologic QDR-2000 and QDR-4500A dual-energy X-ray absorptiometers compared with deuterium dilution. J Pediatr Gastroenterol Nutr (2006) 1.01
Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study. PLoS One (2012) 1.01
Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics (2007) 1.01
Sonography and MR imaging of posterior tibial tendinopathy. AJR Am J Roentgenol (2002) 1.01
Adiponectin and leptin in African Americans. Obesity (Silver Spring) (2008) 1.01
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells (2012) 1.00
Pre-operative assessment enables early diagnosis and recovery of shoulder function in patients with breast cancer. Breast Cancer Res Treat (2010) 1.00
Effects of calcium supplementation on body weight and adiposity in overweight and obese adults: a randomized trial. Ann Intern Med (2009) 0.99
High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet (2004) 0.98
Y-position cysteine substitution in type I collagen (alpha1(I) R888C/p.R1066C) is associated with osteogenesis imperfecta/Ehlers-Danlos syndrome phenotype. Hum Mutat (2007) 0.98